Abbott Laboratories Corporation

Abbvie Inc.

Enanta Pharmaceuticals, Inc.

Enata Pharmacueticals, Inc.

Brian E Green

Keith F McDaniel

Todd Warren Rockway

Dachun Liu

Allan C Krueger

Jason P Shanley

David A Betebenner

Hui-Ju J Chen

Darold L Madigan

Dale J Kempf

John K Pratt

Rolf Wagner

Larry L Klein

Ming Clinton Yeung

Russell Drew Cink

Yat Sun Or

Clarence J Maring

Kent D Stewart

Pamela L Donner

Rong Zhang

Christopher E Motter

David J Grampovnik

Curt S Cooper

David D Anderson

Vincent S Stoll

Teresa A Rosenberg

Daniel P Larson

Todd D Bosse

Guoqiang Wang

John T Randolph

Douglas K Hutchinson

David A DeGoey

Yonghua Gai

Charles A Flentge

Michael D Tufano

Tami J Pilot-Matias

Thomas B Borchardt

M Robert Leanna

Peggy Huang

Dennie S Welch

Albert Wayne Kruger

Mira Hinman

Liangjun Lu

Richard D Bishop

Robert J Carrick

Bradley D Gates

Wenping He

Hongmei Mo

Steven Cramer Cullen

Sherie V L Masse

Akhteruzzaman Molla

Nobuhiko Iwasaki

John R Bellettini

Hing L Sham

Daniel W Norbeck

Xiaoqi Chen

William J Flosi

Jorge Gandarilla

Lin Li

Timothy Middleton

Laura M Maymon

Todd Hopkins

Jorge Gandarllla

Qinghua Xie

Keith F Mcdaniel

Weping He

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Macrocyclic hepatitis C serine protease inhibitors

Phenanthridine macrocyclic hepatitis C serine protease inhibitors

This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.

HCV protease inhibitors and uses thereof

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided.

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

A compound of the formula: ##STR1## is disclosed as a retroviral protease inhibitor compound. Also disclosed are methods and compositions for inhibiting an HIV infection.

Retroviral protease inhibiting compounds

Growing community of inventors

Wonder Lake, IL, United States of America

Brian E Green